Ashlea Kosikowski ๐๐ฅ
@ashleaonair
@1ABmedia Senior Director - Media. Married to @BrianParkeJr, @OhioU @scrippsjschool alum, Lover of Facts. Find me on ๐งต @ ashleakosikowski
ID: 186044654
http://www.1abmedia.com 02-09-2010 13:18:07
24,24K Tweet
5,5K Takipรงi
4,4K Takip Edilen
โListen, I've got something very obvious to tell you. Youโre not allowed to give up. If they decide to kill me, it means that we are incredibly strong.โ - Alexei Navalny My deepest condolences to Alexei Navalnyโs family and friends, to his staff, and to the people of Russia.
Where is Verve Therapeutics headed? Enjoyed chatting with Max Bayer on his FierceBiotech podcast (25 min) 'The Top Line': Gene editing's next act fiercepharma.com/pharma/top-linโฆ
Congratulations Kristina Burow! โฆโฆKristina Burowโฉ Truly a privilege and honor to work with and learn from such an incredible person who is shaping the future of medicine #STATUSList @STATnews statnews.com/status-list/20โฆ
Glad to announce the dosing of the first patient with VERVE-102 in the Heart-2 clinical trial VERVE-102: *in vivo base editor to permanently turn off the PCSK9 gene in liver and durably lower blood LDL-C *delivered using Verve Therapeutics proprietary GalNAc-LNP delivery system as a
.Structure Therapeutics $GPCR - positive top-line Phase 2a obesity data w/ oral, non-peptide, small molecule GLP-1 agonist GSBR-1290. 8:30am ET investor webcast.
"We can make enough material for more than 100 million people..." Structure Therapeutics CEO Ray Stevens speaks about what his company's new oral GLP-1 drug brings to the crowded marketplace:
Our CEO recently spoke w/ CNBC's Fast Money's Lee Melissa to discuss the progress of our #GLP1 receptor agonist drug, GSBR-1290 & its potential to become a best-in-class oral treatment for people living with #obesity. Watch the full clip:ย cnbc.com/video/2024/06/โฆ